hydroxychloroquine

Novartis halts malaria drug trial against COVID-19

Swiss drugmaker Novartis is halting its trial of malaria drug hydroxychloroquine (HCQ) against COVID-19 after struggling to find participants, it said on Friday, as data emerged from other studies raising…

Read More Here

Influential study on hydroxychloroquine withdrawn

An influential article that found hydroxychloroquine increases the risk of death in coronavirus patients has been retracted over data concerns. Three of the study's authors said they could not longer…

Read More Here

Study shows Hydroxychloroquine combination risky for cancer patients with COVID-19

Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30…

Read More Here

UK healthcare workers begin COVID-19 hydroxychloroquine trial

British healthcare workers will on Thursday begin taking part in a University of Oxford-led international trial of two anti-malarial drugs to see if they can prevent COVID-19, including one U.S.…

Read More Here

Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of…

Read More Here

Sanofi to donate 100 million doses of hydroxychloroquine across 50 countries

As of Friday, Sanofi has committed to donating 100 million doses of hydroxychloroquine to 50 countries around the world and has begun to progressively deliver the medicine to authorities…

Read More Here